The recently approved long acting buprenorphine injection Brixadi (TM) can only be administration via what route?
Subcutaneous into the buttock, thigh, abdomen or upper arm. Upon contact with body fluids, Brixadi forms a liquid crystalline gel. Thus, it carries a black box warning for the risk of serious harm or death with intravenous administration.
Submitted by Kristin Reinaker, PharmD, DABAT on behalf of Chandana Singathi, PharmD candidate 2024